Company Overview of Neurimmune Holding AG
Neurimmune Holding AG, a biotechnology company, engages in the development and commercialization of human antibody therapeutics for the treatment and prevention of common human diseases. The company focuses on protein aggregation diseases; and neurodegenerative disorders, such as Alzheimer’s disease. Its pipeline comprises programs in neurodegeneration, including Alzheimer's and Parkinson's diseases, tauopathies, and amyotrophic lateral sclerosis or Lou Gehrig's disease. The company develops human monoclonal antibodies as therapeutics based on its Reverse Translational Medicine technology platform. Neurimmune Holding AG was founded in 2006 and is based in Schlieren, Switzerland.
Founded in 2006
41 44 755 46 46
41 44 755 46 47
Key Executives for Neurimmune Holding AG
Neurimmune Holding AG Key Developments
Similar Private Companies By Industry
|AB2 Bio Ltd.||Europe|
|ADC Products Switzerland SARL||Europe|
|ADC Therapeutics SA||Europe|
|AlloCyte Pharmaceuticals AG||Europe|
Recent Private Companies Transactions
December 7, 2016
|AL-S Pharma AG|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Neurimmune Holding AG, please visit www.neurimmune.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.